Immunoreactivity and Guanosine 3',5'-Cyclic Monophosphate Activating Actions of Various Molecular Forms of Human B-Type Natriuretic Peptide

Hypertension - United States
doi 10.1161/hypertensionaha.106.081083
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

C-Type Natriuretic Peptide Inhibits Thrombin- And Angiotensin II- Stimulated Endothelin Release via Cyclic Guanosine 3',5'-Monophosphate

Hypertension
Internal Medicine
1992English

Guanosine 3',5'-Monophosphate and Adenosine 3',5'-Monophosphate Content of Human Umbilical Artery.

Journal of Clinical Investigation
Medicine
1975English

Regulation of Synthesis of Guanosine 3′:5′-Cyclic Monophosphate in Neuroblastoma Cells

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
1978English

Tissue Guanosine-3′,5′-Cyclic Monophosphate Levels and Soluble Guanylate Cyclase Activity

Journal of Clinical Investigation
Medicine
1978English

Effects of Glucagon on Adenosine 3′,5′-Monophosphate and Guanosine 3′,5′-Monophosphate in Human Plasma and Urine

Journal of Clinical Investigation
Medicine
1970English

The Effect of Insulin on Adenosine 3′:5′-Monophosphate and Guanosine 3′:5′-Monophosphate Concentrations in Human Plasma

Clinical Science
1976English

Emergence of Cyclic Guanosine 3':5'-Monophosphate-Dependent Protein Kinase Immunoreactivity in Developing Rhesus Monkey Cerebellum: Correlative Immunocytochemical and Electron Microscopic Analysis

Journal of Neuroscience
Neuroscience
1984English

Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase

Circulation
Cardiovascular MedicinePhysiologyCardiology
2003English

Renal Interstitial Guanosine Cyclic 3', 5'-Monophosphate Mediates Pressure-Natriuresis via Protein Kinase G

Hypertension
Internal Medicine
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy